QCG
JUNO

Quadrant Capital Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Quadrant Capital Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-57
Closed -$2K – 2279
2017
Q4 		$2K Hold
57
– – ﹤0.01% 1885
2017
Q3 		$2K Hold
57
– – ﹤0.01% 1897
2017
Q2 		$1K Hold
57
– – ﹤0.01% 1815
2017
Q1 		$1K Sell
57
-2,046
-97% -$43.9K ﹤0.01% 1993
2016
Q4 		$39K Buy
2,103
+23
+1% +$563 0.02% 519
2016
Q3 		$62K Buy
+2,080
New +$64.7K 0.04% 367
2016
Q1 		– Sell
-185
Closed -$8K – 2123
2015
Q4 		$8K Hold
185
– – 0.01% 896
2015
Q3 		$7K Buy
+185
New +$8.11K ﹤0.01% 762

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Quadrant Capital Group's JUNO Position: Q1 2018 in Review

Quadrant Capital Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 57 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in JUNO in Q3 2015 and held it in 8 quarters. The position peaked at $62K in Q3 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Quadrant Capital Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Quadrant Capital Group sold 57 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $2K.
  • Quadrant Capital Group first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 8 quarters.
  • Quadrant Capital Group's Juno Therapeutics, Inc. position peaked at $62K in Q3 2016.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Quadrant Capital Group's 13F filing for Q1 2018, filed 10 May 2018.